title: Effect of BSO and etanidazole on neurofilament degradation in neonatal rat spinal cord cultures.
abstract: Peripheral neuropathy is the major dose-limiting toxicity of the hypoxic cell sensitiser, etanidazole. Previous work from this laboratory using culture neuronal cell lines suggested that nitroimidazole-induced degradation of neurofilament proteins might be the critical biological event mediating this neurotoxicity. The purpose of the present study was to develop the neurofilament degradation assay in an organotypic spinal cord culture system with the goal of developing strategies for optimising sensitiser efficacy as well as ameliorating nitroimidazole-induced neurotoxicity. Spinal cord cultures were treated with etanidazole and neurofilament protein degradation was analysed by immunoblot analysis. Spinal cord cultures exposed to etanidazole exhibited a dose-dependent loss of parent neurofilament proteins, with concomitant appearance of low molecular weight degradation products. The potential neurotoxic effect of L, S-buthionine sulphoximine (BSO), a compound that enhances the radiosensitising effectiveness of 2-nitroimidazoles, was also screened in this assay system. BSO alone, at concentrations up to 100 microM, did not promote neurofilament degradation. BSO (20 microM) enhanced the effect of etanidazole on neurofilament degradation by a dose-modifying factor of 1.6 +/- 0.5. Since 20 microM BSO is expected to enhance etanidazole radiosensitisation of hypoxic cells by a larger factor, this suggests that a therapeutic gain could be achieved using BSO in combination with etanidazole in radiation therapy.
authors.affiliation: Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: S T
authors.initials: ST
authors.lastname: Palayoor
authors.forename: E A
authors.initials: EA
authors.lastname: Bump
authors.forename: D M
authors.initials: DM
authors.lastname: Saroff
authors.forename: J R
authors.initials: JR
authors.lastname: Delfs
authors.forename: C
authors.initials: C
authors.lastname: Geula
authors.forename: L
authors.initials: L
authors.lastname: Menton-Brennan
authors.forename: S J
authors.initials: SJ
authors.lastname: Hurwitz
authors.forename: C N
authors.initials: CN
authors.lastname: Coleman
authors.forename: M A
authors.initials: MA
authors.lastname: Stevenson
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019328:Buthionine Sulfoximine / Q000494:pharmacology*; D004357:Drug Synergism; D017341:Etanidazole / Q000494:pharmacology*; D016900:Neurofilament Proteins / Q000378:metabolism*; D009924:Organ Culture Techniques; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D051381:Rats; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D016900:Neurofilament Proteins; D011838:Radiation-Sensitizing Agents; D013481:Superoxides; D017341:Etanidazole; D019328:Buthionine Sulfoximine